Regeneron brings out the budget ax as execs cut staff in the wake of revising alliance with Sanofi
Sanofi’s move to reorganize the company and revise its commercial pact with Regeneron is costing jobs — at Regeneron.
The two players announced on December 10 that they are restructuring their alliance on Kevzara and Praluent, with the French pharma giant taking sole global rights to Kevzara and ex-US rights to Praluent. In a quick response, Regeneron filed a WARN notice with the state of New York just ahead of Christmas that it is chopping 15 jobs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.